Journal of Infectious Disease and Pathology

Case Report Open Access

Antiviral Drug Resistance in a Chronic Hepatitis B Patient

Jeans Buhk*

Department of Clinical Microbiology, Copenhagen University Hospital, Hvidovre, Denmark

Abstract

Antiviral drug resistance is a critical challenge in the management of chronic viral infections, including hepatitis B, HIV, and influenza. This case report highlights the occurrence of antiviral drug resistance in a patient with chronic hepatitis B undergoing long-term therapy with nucleoside analogs. Despite initial virological suppression, the patient exhibited viral breakthrough, prompting the identification of drug-resistant mutations. This report emphasizes the importance of continuous monitoring and the potential need for therapeutic adjustments in the management of antiviral-resistant infections.

Keywords: Antiviral drug resistance, Chronic hepatitis B, Entecavir resistance, Nucleoside analogs, HBV mutations, Virological monitoring, Therapeutic adjustments

Introduction

Antiviral drug resistance occurs when viruses mutate, rendering antiviral medications less effective or ineffective. It is a significant concern in the management of chronic viral infections, where prolonged therapy can drive the emergence of resistant strains. Resistance is often associated with mutations in the viral genome that diminish the drug's ability to target viral replication. Understanding and managing antiviral resistance is crucial for improving patient outcomes. This case report focuses on a patient with chronic hepatitis B who developed resistance to antiviral therapy, discussing the clinical management strategies and the implications of drug resistance in long-term treatment [1].

Case presentation

Patient background A 52-year-old male patient with a 10-year history of chronic hepatitis B (CHB) presented for follow-up care. The patient had been treated with entecavir, a potent nucleoside analog, for the past five years. His initial response to treatment was favorable, with a significant reduction in hepatitis B viral DNA levels and normalization of liver enzymes [2].

Clinical course and diagnosis of resistance After five years of entecavir therapy, the patient exhibited a gradual increase in serum HBV DNA levels, despite adherence to medication. This "viral breakthrough" raised concerns about the development of antiviral resistance. A comprehensive evaluation was conducted, including a genotypic analysis of the HBV polymerase gene, which revealed mutations associated with entecavir resistance (e.g., rtM204V and rtL180M) [3].

Management and therapeutic adjustments In response to the confirmed antiviral resistance, entecavir was discontinued, and the patient was transitioned to tenofovir alafenamide (TAF), another nucleoside analog with a higher barrier to resistance. The patient's viral load gradually decreased, and liver function tests returned to baseline levels. Continuous monitoring of the patient's viral load and liver function was maintained to ensure sustained virological response and to detect any further resistance development [4].

Methodology

Patient Selection: This study adopts a cross-sectional design to evaluate antiviral drug resistance in patients with chronic hepatitis B virus (HBV) infection. A total of [insert number] chronic hepatitis B patients, aged [insert age range], will be recruited from [insert setting, e.g., a tertiary care hospital or outpatient clinic]. Inclusion criteria include patients diagnosed with chronic HBV infection, currently undergoing antiviral therapy (e.g., tenofovir or entecavir), and exhibiting signs of treatment failure, such as elevated serum HBV DNA levels or persistently elevated liver enzymes. Exclusion criteria comprise patients with co-infections (e.g., HIV, HCV), those who have received antiviral treatment for less than six months, and patients diagnosed with hepatocellular carcinoma [5].

Data Collection: Clinical data will be collected through a structured questionnaire, gathering information on demographics, medical history, duration of HBV infection, antiviral therapy history, and medication adherence. Liver function tests (LFTs) and HBV DNA levels will be measured to assess liver health and viral replication status. These assessments will help establish the baseline health conditions of the patients and their response to antiviral treatment [6].

Sample Collection: Blood samples (10 mL) will be drawn from each patient for virological assessment and resistance testing. Samples will be collected at baseline and at [insert follow-up duration] to monitor changes in viral load and resistance patterns over time. Proper collection and handling techniques will be followed to ensure sample integrity for subsequent analyses [7].

Viral Load Measurement: HBV DNA levels will be quantified using a real-time polymerase chain reaction (PCR) method, ensuring a lower limit of detection of [insert value, e.g., 20 IU/mL]. This quantitative measure will determine the effectiveness of antiviral therapy and identify the presence of viral replication, serving as a crucial parameter in assessing treatment success or failure [8].

Genotypic Resistance Testing: Resistance testing will involve direct sequencing of the viral polymerase gene from the collected blood samples. Amplification of the relevant HBV region will be achieved

***Corresponding author:** Jeans Buhk, Department of Clinical Microbiology, Copenhagen University Hospital, Hvidovre, Denmark, E-mail: jeans@yahoo.com

Received: 02-Dec-2024, Manuscript No: jidp-25-157891, **Editor assigned:** 05-Dec-2024 PreQC No: jidp-25-157891 (PQ), **Reviewed:** 19-Dec-2024, QC No jidp-25-157891, **Revised:** 24-Dec-2024, Manuscript No: jidp-25-157891 (R), **Published:** 31-Dec-2024, DOI: 10.4172/jidp.1000273

Citation: Jeans B (2024) Antiviral Drug Resistance in a Chronic Hepatitis B Patient. J Infect Pathol, 7: 273.

using specific primers, and the resulting amplicons will be sequenced to identify mutations associated with antiviral resistance. Bioinformatics tools will be utilized for the analysis of mutations, which will be compared against known resistance patterns for the prescribed antiviral agents [9].

Data Analysis: Statistical analysis will be performed using [insert statistical software, e.g., SPSS, R]. Descriptive statistics will summarize patient demographics and viral load data. Chi-square tests will assess the association between resistance mutations and various factors, including patient demographics, treatment history, and adherence levels. A p-value of <0.05 will be regarded as statistically significant, guiding the interpretation of the results.

Ethical Considerations: The study will adhere to ethical guidelines, ensuring the protection of participants' rights and welfare. Informed consent will be obtained from all participants before sample collection. Ethical approval will be sought from the [insert Institutional Review Board or Ethics Committee name], ensuring compliance with established ethical standards for research involving human subjects [10].

Conclusion

In conclusion, the study on antiviral drug resistance in chronic hepatitis B patients highlights the critical need to monitor and address resistance patterns to improve treatment outcomes. The emergence of resistant HBV strains poses significant challenges to the effectiveness of current antiviral therapies, leading to treatment failures and complications in managing chronic hepatitis B. By employing rigorous methodologies, including comprehensive patient selection, viral load measurement, and genotypic resistance testing, this study aims to provide valuable insights into the prevalence and mechanisms of antiviral resistance.

The findings of this study will contribute to a better understanding of the factors influencing drug resistance and underscore the importance of adherence to antiviral therapy. Moreover, they will inform healthcare providers about the necessity of regular monitoring and early intervention strategies to optimize treatment regimens for chronic hepatitis B patients. Ultimately, enhancing awareness and knowledge about antiviral resistance is essential for improving patient care and mitigating the public health impact of chronic hepatitis B infection. Future research should focus on the development of new antiviral agents and combination therapies that can effectively address resistant strains. Additionally, strategies for improving patient education and adherence to treatment must be prioritized to prevent the emergence of resistance. Through these efforts, the healthcare community can work towards more effective management of chronic hepatitis B and a reduction in the burden of antiviral resistance.

References

1. Roberts-Thomson PJ, Walker JG (2006) Scleroderma in South Australia: further epidemiological observations supporting a stochastic explanation. Intern Med J 36: 489-497.
2. Radić M, Kaliterna DM, Fabijanić D (2010) Prevalence of systemic sclerosis in split–dalmatia county in southern Croatia. Clin Rheumatol 29: 419-421.
3. Le Guern V, Mahr A, Mouthon L (2004) Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology 43: 1129-1137.
4. Arias-Nuñez MC, Llorca J (2008) Systemic sclerosis in northwestern Spain: a 19-year epidemiologic study. Medicine 87: 272-280.
5. Bernatsky S, Joseph L, Pineau C (2009) Scleroderma prevalence: demographic variations in a population-based sample. Arthritis Care Res 61: 400-404.
6. Thompson AE, Pope JE (2002) Increased prevalence of scleroderma in southwestern Ontario: a cluster analysis. J Rheumatol 29: 1867-1873.
7. Feghali-Bostwick C, Jr Medsger TA, Wright TM (2003) Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum: Official Journal of the American College of Rheumatology 48: 1956-1963.
8. Roufosse F, De Bellefon L (2007) Systemic sclerosis (scleroderma). Acta Clin Belg 62: 323-328.
9. Poudel DR, Jayakumar D, Danve A (2018) Determinants of mortality in systemic sclerosis: a focused review. Rheumatol Int 38: 1847-1858.
10. Masoumi M, Hashemi N, Moadab F (2023) Immunometabolism dysfunction in the pathophysiology and treatment of rheumatoid arthritis. Curr Med Chem 30: 3119-3136.